X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Traditional treatment methods typically involve surgery, which may have a risk of scarring or loss of function, treatment with Rhenium-SCT (Rhenium-188) employs a non-invasive superficial application of a paste containing ß-emitting particles directly to the lesion.
Lead Product(s): Rhenium-188
Therapeutic Area: Oncology Product Name: Rhenium-SCT
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Avion Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 23, 2022
Details:
The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.
Lead Product(s): Rhenium-188
Therapeutic Area: Oncology Product Name: Rhenium-188
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: NanoMab Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
